Clinical trials: Partial Lipodystrophy
Healthy, Lipodystrophy, Familial Partial
Lipodystrophy and Fat Metabolism During Exercise
Mandibular dysplasia with deafness and progeroid features (MDP) syndrome is a rare genetic metabolic disorder that causes lipodystrophy: the inability of the body to store subcutaneous adipose tissue (fat under the skin).
- Trial name
- FAT (NCT04056000)
- Testing
- Caffeine, High-carbohdyrate breakfast, 60-minutes of steady state exercise
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Exeter
Lipodystrophy
Feasibility of Adipose Tissue Triglyceride (TG) Labelling in Familial Partial Lipodystrophy (FPLD)
Background: People with familial partial lipodystrophy (FPLD) do not store fat in the body normally. This can lead to serious illnesses such as diabetes and heart disease.
- Trial name
- NCT05996536
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Lipodystrophy, Partial
Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024
This study aims to see if the clinical use of Tirzepatide in patients with lipodystrophy (a rare disorder associated with abnormal loss of the body's fat tissue) may lead to improved diabetes mellitus control and lowering of…
- Trial name
- TILT-2024 (NCT07091734)
- Testing
- Tirzepatide, Usual care medications
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Michigan
Lipodystrophy
Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension
Background: Partial lipodystrophy is a deficiency of body fat in parts of the body (usually the arms and legs). People with partial lipodystrophy often get high blood triglyceride (fat) level, insulin resistance, diabetes and…
- Trial name
- NCT02639286
- Testing
- ISIS 304801
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Familial Partial Lipodystrophy Type 2
Study of Cortisol Metabolism in Familial Partial Lipodystrophy Type 2
Familial partial lipodystrophic syndromes are characterized by an increase in visceral adipose tissue and an atrophy of subcutaneous adipose tissue.
- Trial name
- LIPOCORT (NCT04845165)
- Testing
- Biopsy
- Where
- France
- Volunteers
- 25 people
- Sponsor
- University Hospital, Lille
Partial Lipodystrophy
Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
This is an Open Label, Phase IV, Post Authorisation Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in people with Partial Lipodystrophy
- Trial name
- NCT06484868
- Testing
- Metreleptin
- Where
- 12 sites in France, Germany and 2 more
- Volunteers
- 12 people
- Sponsor
- Amryt Pharma
Familial Partial Lipodystrophy, Metabolic Abnormalities
A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)
Two cohorts are being studied based on leptin levels. Cohort A is composed of patients with baseline leptin <8.0 ng/mL and Cohort B is composed of patients with baseline leptin 8.0 to ≤20.0 ng/mL The primary objectives will be…
- Trial name
- LEAP (NCT05088460)
- Testing
- REGN4461
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 20 people
- Sponsor
- Regeneron Pharmaceuticals
Familial Partial Lipodystrophy, Hypertriglyceridemia
Study of Gemcabene in Adults With FPLD
The overall objective of this study is to assess the efficacy and safety of two dosing regimens of gemcabene (300 mg once daily for 24 weeks or 300 mg daily for 12 weeks followed by 600 mg daily for 12 weeks) in up to eight…
- Conditions
- Familial Partial Lipodystrophy, Hypertriglyceridemia, Fatty Liver, NASH - Nonalcoholic Steatohepatitis
- Trial name
- NCT03508687
- Testing
- 300mg Gemcabene, 600mg Gemcabene
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Elif Oral
Lipodystrophy, Dunnigan Syndrome
Exploratory Study of the Relationships Between the Biomarkers of Inflammation, Lipidome and Insulin Resistance and Disorders of Glycemic Regulation in a Cohort of Insulin-resistant Subjects Due to Excess Weight or Dunnigan's Lipodystrophy
The objective of this work is to identify biomarkers of interest in patients with insulin resistance leading to early disorders of glycemic regulation.
- Trial name
- IRAP-DUN 2 (NCT05424913)
- Testing
- research-specific blood sample
- Where
- Reunion
- Volunteers
- 150 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Lipodystrophy
Lipodystrophy Connect Patient Registry
Lipodystrophy Connect is an online survey tool designed to collect demographic data and health information from individuals with Lipodystrophy.
- Trial name
- NCT02577952
- Where
- United States
- Volunteers
- 257 people, healthy volunteers welcome
- Sponsor
- PatientCrossroads
Familial Partial Lipodystrophy, Nonalcoholic Steatohepatitis
CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy
The study investigators' aim is to determine the long term safety and efficacy of Metreleptin (Myalept,) in promoting amelioration of metabolic abnormalities in patients with all forms of partial lipodystrophy.
- Conditions
- Familial Partial Lipodystrophy, Nonalcoholic Steatohepatitis, NAFLD
- Trial name
- NCT02654977
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Michigan
Lipodystrophy
Assess the Possibility of Diagnosing Diabetes and Rediabetes Following Oral Induced Hyperglycemia in Patients With Dunnigan's Partial Familial Lipodystrophy by Replacing 75 g of Glucose With a Standardized Carbohydrate Breakfast and Continuous Interstitial Monitoring Glucose)
Dunnigan's syndrome is a partial familial lipodystrophy due to a mutation in the Lamine A LMNA gene. This very rare syndrome is 20 times more common in Réunion compared to the rest of Europe with several families suffering from a…
- Trial name
- HGPO-DUN (NCT05789251)
- Testing
- Standardized breakfast
- Where
- Reunion
- Volunteers
- 54 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Partial Lipodystrophy
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy.
- Trial name
- METRE-PL (NCT05164341)
- Testing
- metreleptin
- Where
- 31 sites in United States, Belgium and 7 more
- Volunteers
- 69 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Vascular Ehlers-Danlos Syndrome, Vascular Ehlers Danlos Syndrome
Metabolic Phenotyping in vEDS
This research study will investigate whether people with vascular Ehlers-Danlos syndrome (vEDS), a rare inherited condition, have problems with the way their body stores and uses fat (adipose tissue).
- Conditions
- Vascular Ehlers-Danlos Syndrome, Vascular Ehlers Danlos Syndrome, Vascular EDS (vEDS)
- Trial name
- MPEDS (NCT07516496)
- Testing
- No intervention, observational
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Lipodystrophy Acquired, Lipodystrophy Congenital
Registry for Patients With Lipodystrophy
Given the lack of knowledge on lipodystrophies, the medical and social responsibility for the persons affected by it calls for the monitoring of the progression over long periods of time.
- Trial name
- ECLip Registry (NCT03553420)
- Where
- 28 sites in Austria, France and 14 more
- Volunteers
- 5,000 people
- Sponsor
- University of Ulm
Generalised Lipodystrophy, Partial Lipodystrophy
MEASuRE: Metreleptin Effectiveness And Safety Registry
The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.
- Trial name
- MEASuRE (NCT02325674)
- Testing
- Metreleptin
- Where
- 28 sites in United States, France and 3 more
- Volunteers
- 100 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Lipodystrophy Congenital Generalized, Lipodystrophy, Familial Partial
Sexual Quality of Life in Female Patients With Lipodystrophy Syndromes or Turner's Syndrome: a Case-control Study
Turner syndrome (TS) and congenital lipodystrophy syndromes (LS) are rare conditions with major consequences on cardiometabolic health, fertility, and body morphology.
- Conditions
- Lipodystrophy Congenital Generalized, Lipodystrophy, Familial Partial, Turner Syndrome
- Trial name
- LIPTURN (NCT07799012)
- Where
- France
- Volunteers
- 1,416 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Familial Partial Lipodystrophy
Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)
This is a single-center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for reduction of fasting triglycerides in participants with familial partial lipodystrophy.
- Trial name
- NCT03514420
- Testing
- AKCEA-ANGPTL3-LRx
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Akcea Therapeutics
Generalized Lipodystrophy
Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy
This study is researching a new drug called mibavademab (called "study drug"). The study involves participants with a condition called Generalized Lipodystrophy (GLD).
- Trial name
- LAGO (NCT07220785)
- Testing
- Mibavademab
- Where
- 9 sites in United States, Brazil and 1 more
- Volunteers
- 28 people
- Sponsor
- Regeneron Pharmaceuticals
High Cholesterol, Lipodystrophy, Familial Partial
The Benefits of the Measureof Epicardial Adipose Tissue During Coronary Calcium Assessment of the Refine Cardiovascular Risk Assessment at Reunion Island.
The goal of this retrospective study is to see whether patients with familial partial type 2 lipodystrophy, who are at high cardiovascular risk present a higher volume of visceral epicardial adipose tissue than other patients…
- Conditions
- High Cholesterol, Lipodystrophy, Familial Partial, Diabetes
- Trial name
- EPICAC-RUN (NCT07090629)
- Testing
- Epicardial adipose tissue measurement on the available tododensitometry used for coronary calcium scoring
- Where
- Reunion
- Volunteers
- 126 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion